0 (0%) | 03-29 05:41 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 6.25 | 1-year : | 7.06 |
Resists | First : | 5.35 | Second : | 6.05 |
Pivot price | 4.97 | |||
Supports | First : | 4.23 | Second : | 3.51 |
MAs | MA(5) : | 4.76 | MA(20) : | 5.11 |
MA(100) : | 5.04 | MA(250) : | 6.66 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 11.1 | D(3) : | 10.3 |
RSI | RSI(14): 47.5 | |||
52-week | High : | 11.35 | Low : | 3.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed above bottom band by 28.4%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.96 - 4.98 | 4.98 - 5 |
Low: | 4.69 - 4.73 | 4.73 - 4.75 |
Close: | 4.73 - 4.78 | 4.78 - 4.82 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Thu, 28 Mar 2024
Novavax Inc (NVAX) is down 1.03% Thursday In Premarket Trading - InvestorsObserver
Sat, 09 Mar 2024
1 Beaten-Down Stock That's Still Not Worth Buying - The Motley Fool
Thu, 07 Mar 2024
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street - Yahoo Finance
Sat, 02 Mar 2024
Earnings Update: Novavax, Inc. (NASDAQ:NVAX) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
Wed, 28 Feb 2024
NVAX Stock Alert: 9 Reasons Why Novavax Investors Are So Disappointed Today - InvestorPlace
Wed, 28 Feb 2024
Novavax stock falls 20% as vaccine maker misses quarterly estimates, sees sluggish 2024 sales - CNBC
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 140 (M) |
Shares Float | 125 (M) |
Held by Insiders | 5 (%) |
Held by Institutions | 56.3 (%) |
Shares Short | 52,740 (K) |
Shares Short P.Month | 52,090 (K) |
EPS | -5.41 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -5.14 |
Profit Margin | -55.5 % |
Operating Margin | -63.1 % |
Return on Assets (ttm) | -17.1 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | -18.5 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 7.02 |
EBITDA (p.s.) | -3.66 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -714 (M) |
Levered Free Cash Flow | -979 (M) |
PE Ratio | -0.89 |
PEG Ratio | 0 |
Price to Book value | -0.93 |
Price to Sales | 0.68 |
Price to Cash Flow | -0.94 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |